What the Latest Prostate Cancer Research Actually Tells You to Do.

Two studies landed recently. Here is the part that is relevant to you.

There has been significant prostate cancer news in quick succession. A UCL trial found a new way to identify failing treatment far earlier than was previously possible. A separate European study made the strongest case yet for a national screening programme in the UK. Both are genuinely significant.

But neither changes what is available to men today. So here is what this article focuses on:

• What the UCL blood test trial found and why it matters for treatment
• What the European screening study showed and what it means for UK men
• Why PSA monitoring remains the most accessible tool men have right now
• What to do before a national programme arrives

The research is pointing clearly in one direction. This breaks down what that direction actually looks like in practice.

Most men do not think about their prostate until something prompts them to. A symptom, a conversation with a GP, a friend's diagnosis. By the time any of those things happen, a lot of time has usually passed without any monitoring at all.

Two significant research developments have arrived at the same moment, both pointing toward the same conclusion: earlier detection changes outcomes. A University College London study has found a way to identify men whose treatment is failing far sooner than current methods allow. And a large European study has produced the clearest evidence yet that targeted prostate cancer screening reduces deaths, with a UK decision on a national programme expected before the end of the year.

Neither of these is available to most men right now. But both make the case for not waiting any clearer than it has been before.

What the UCL trial found

The University College London study involved 117 men with newly diagnosed metastatic prostate cancer, meaning cancer that had already spread, across 14 NHS sites. Researchers looked at whether testing for tiny fragments of tumour DNA circulating in the blood could detect whether cancer was continuing to grow during treatment.

Three in ten men had detectable tumour DNA in their blood after six to twelve weeks of treatment. When that DNA result was combined with PSA levels, it identified men who were twenty times more likely to die than those with undetectable tumour DNA and low PSA. The predictive gap between those two groups is striking.

The researcher who led the study described it as the first time such a clear link had been established between tumour DNA in the blood and outcomes in men with hormone-sensitive advanced cancer. The goal is to use this signal early enough to adjust treatment before it becomes clear through other means that something is not working. The next step is reproducing the findings across clinical trials before it can be rolled out more widely.

What the European screening study showed

A separate study, published in the New England Journal of Medicine, has strengthened the argument for a national prostate cancer screening programme in the UK. Researchers analysed data across eight European countries over 23 years, covering 162,000 men, 72,000 of whom were invited to participate in screening.

Targeted screening was associated with a 13 per cent reduction in prostate cancer deaths. One death was prevented for every 456 men invited for screening, and one death was averted for every 12 men in whom cancer was diagnosed. Commentators noted those figures are comparable to outcomes seen with breast and bowel cancer screening programmes, which are already established in the UK.

The research specifically advocates for a targeted approach to address the longstanding concern about overdiagnosis, where men are treated for cancers that may never have caused harm. A decision on whether to introduce a UK programme is anticipated before the end of the year.

Where each development currently stands

Why PSA sits at the centre of both

Both research developments reinforce something that has been consistent for years. PSA, prostate specific antigen, remains the central marker in prostate health monitoring. The UCL study used PSA alongside the new DNA test to produce its most predictive results. The European screening study is built around PSA-based detection. Whatever comes next, PSA is not being replaced or superseded.

PSA measures a protein produced by the prostate gland. Elevated levels can indicate cancer, but can also reflect a benign enlarged prostate or inflammation. A high reading is not a diagnosis. It is a signal that something is worth investigating, which is precisely its value as a monitoring tool.

For men who are not within any formal screening programme, which currently means most men in the UK, tracking PSA over time is the most accessible way to build a picture of prostate health. A baseline reading taken now gives a GP something to compare against in future. That comparison is where changes become detectable.

What men can actually do right now

The national programme has not arrived yet. The UCL DNA test is not in clinical use. That leaves a gap, and the most practical way to fill it is to understand where PSA levels currently sit. A GP can request the test, but a routine appointment is not the only route.

Home PSA testing has become increasingly accessible for men who want to monitor prostate health between clinical visits or before raising it with a doctor. Berkeley Health's PSA rapid test kit is designed for home use without clinical training, with results in minutes. Having a result in hand changes the nature of a GP conversation from vague concern to a specific data point worth discussing.

The men for whom a PSA baseline is most relevant right now include:

• Men aged 45 and over, with or without symptoms
• Those with a father or brother diagnosed with prostate cancer
• Black men, who face a significantly higher lifetime risk
• Men with urinary changes such as weaker flow or increased frequency
• Anyone who wants a baseline in place before a national programme arrives

Getting ahead of a system that has not caught up yet

The research is clear and moving quickly. A national programme may be months away. New tools for tracking treatment response are being trialled across NHS sites right now. But for men making health decisions today, none of that has landed yet.

A home PSA test is the most practical bridge available. It does not replace clinical care, and any elevated result always warrants follow-up with a GP. But it puts something concrete in a man's hands without waiting for a system that is still coming together.

You can find Berkeley Health's PSA rapid test kit at berkeleyhealth.com.

Frequently asked questions